Drugs in Dev.
Immunology
Discovery Platform
China 
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : P014
Therapeutic Area : Immunology
Study Phase : Discovery Platform
Sponsor : Quan Capital
Deal Size : $46.0 million
Deal Type : Financing
Kira Pharmaceuticals Launches to Pioneer Novel Therapeutics for Complement-Mediated Diseases
Details : Kira's most advanced program, P014, is a first-in-class biologic drug with a unique mechanism of action designed to inhibit both upstream and downstream complement targets.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
November 12, 2020
Lead Product(s) : P014
Therapeutic Area : Immunology
Highest Development Status : Discovery Platform
Sponsor : Quan Capital
Deal Size : $46.0 million
Deal Type : Financing
